A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with ras-wild metastatic colorectal cancer: A collaborative study by Turkish oncology group (tog)

Simple item page
dc.contributor.authorDegirmencioglu S.
dc.contributor.authorTanriverdi O.
dc.contributor.authorMenekse S.
dc.contributor.authorDogan M.
dc.contributor.authorHacioglu B.
dc.contributor.authorOktay E.
dc.contributor.authorErdem D.
dc.contributor.authorArpaci E.
dc.contributor.authorUluc B.O.
dc.contributor.authorTurhal S.
dc.contributor.authorYilmaz M.
dc.contributor.authorPilanci K.N.
dc.contributor.authorSakin A.
dc.contributor.authorAraz M.
dc.contributor.authorCokmert S.
dc.contributor.authorOzdemir O.
dc.contributor.authorSen E.
dc.contributor.authorNayir E.
dc.date.accessioned2024-07-22T08:09:08Z
dc.date.available2024-07-22T08:09:08Z
dc.date.issued2019
dc.description.abstractPurpose: To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab. Methods: This retrospective multicenter observational study involved a total of 238 patients who received chemotherapy in combination with either bevacizumab or cetuximab or panitumumab as first-line therapy for KRAS wild-type metastatic colorectal cancer. Patients with full medical records having pathological diagnosis of CRC adenocarcinoma were included in the study. The demographic, laboratory, histopathological and clinical characteristics of the patients were determined, and three groups were compared based on the study variables. Results: The mean age of the entire sample (n=238) was 58±11 years, 64% of which were male. The most frequent tumor localization was the rectum (37%) and G2 was the most common tumor grade (59.7%). About 63% of the patients had metastatic disease at diagnosis, with the most common site of metastasis being lung (14.7%) and liver (52.5%). Overall survival (OS) was 63.9%, while 1-, 3- And 5-year survival rates were 91.7, 56.6 and 36.9%, respectively. The expected mean survival was 49.1 months (95% CI, 42.9-55.3). The 1-, 3- And 5-year progression-free survival (PFS) rates following first-line treatment were 65.3, 26.1 and 5.6%, respectively, while disease free survival (DFS) in patients without metastasis at diagnosis was 68.5%. An analysis carried out disregarding which treatment the patients received (FOLFOX or FOLFIRI) revealed that a panitumumab-containing combination resulted in poorer prognosis compared to bevacizumab or cetuximab-containing combination (p<0.001). With regard to the adverse effect profile, the most common adverse effects were neuropathy and neutropenia in patients receiving FOLFOX-bevacizumab; neutropenia and perforation in patients receiving FOLFIRI-bevacizumab; rash and pustular infection in patients receiving FOLFIRI-cetuximab; and diarrhea in patients who received FOLFIRI-panitumumab combination. Conclusion: is the first multicenter study performed in Turkey evaluating the response to treatment and adverse effects in patients with KRAS wild-type metastatic colorectal cancer. © 2019 Zerbinis Publications. All Rights Reserved.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14676
dc.language.isoEnglish
dc.publisherZerbinis Publications
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBevacizumab
dc.subjectCetuximab
dc.subjectColorectal Neoplasms
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectLiver Neoplasms
dc.subjectLung Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMutation
dc.subjectPanitumumab
dc.subjectPrognosis
dc.subjectProto-Oncogene Proteins p21(ras)
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectTurkey
dc.subjectbevacizumab
dc.subjectcetuximab
dc.subjectfluorouracil
dc.subjectfolinic acid
dc.subjectirinotecan
dc.subjectK ras protein
dc.subjectoxaliplatin
dc.subjectpanitumumab
dc.subjectantineoplastic agent
dc.subjectbevacizumab
dc.subjectcetuximab
dc.subjectKRAS protein, human
dc.subjectpanitumumab
dc.subjectprotein p21
dc.subjectacute kidney failure
dc.subjectadult
dc.subjectaged
dc.subjectanemia
dc.subjectArticle
dc.subjectblood transfusion
dc.subjectcancer combination chemotherapy
dc.subjectcancer immunotherapy
dc.subjectcancer prognosis
dc.subjectcancer survival
dc.subjectcolorectal carcinoma
dc.subjectconstipation
dc.subjectcontrolled study
dc.subjectdeep vein thrombosis
dc.subjectdehydration
dc.subjectdiarrhea
dc.subjectdisease free survival
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectepistaxis
dc.subjectfebrile neutropenia
dc.subjectfemale
dc.subjecthand foot syndrome
dc.subjectheart arrhythmia
dc.subjecthuman
dc.subjectileus
dc.subjectinfection
dc.subjectintestine perforation
dc.subjectlung embolism
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmalignant hypertension
dc.subjectmedical record review
dc.subjectmetastatic colorectal cancer
dc.subjectmucosa inflammation
dc.subjectnail disease
dc.subjectnausea and vomiting
dc.subjectneuropathy
dc.subjectneutropenia
dc.subjectobservational study
dc.subjectoverall survival
dc.subjectprogression free survival
dc.subjectproteinuria
dc.subjectrash
dc.subjectretrospective study
dc.subjectsurvival rate
dc.subjectthrombocytopenia
dc.subjecttumor localization
dc.subjectclinical trial
dc.subjectcolorectal tumor
dc.subjectfollow up
dc.subjectgenetics
dc.subjectliver tumor
dc.subjectlung tumor
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectmutation
dc.subjectpathology
dc.subjectprognosis
dc.subjectsecondary
dc.subjectturkey (bird)
dc.subjectvery elderly
dc.titleA retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with ras-wild metastatic colorectal cancer: A collaborative study by Turkish oncology group (tog)
dc.typeArticle

Files

Collections

Scopus Koleksiyonu